Clinical Endpoint with Polymerase

Side effects and complications in the use of drugs: paroxysmal feeling the heat (hot bloodsucker nausea, fatigue, sweating and dizziness, headache, insomnia, abdominal pain, anorexia, depression, alopecia, peripheral edema (swelling of feet, shanks), constipation or indigestion, reduced episodes of lymphocytes (especially in patients with initial lymphopenia, but the average level of lymphocytes in quite a long time in these patients did not change significantly), thrombocytopenia, leukopenia, increase of liver function tests in serum and increased alkaline phosphatase (primarily patients with metastases to the liver and bones, as well as the presence of other liver diseases). Method of production of drugs: Table., Coated tablets, 1 mg № 28. Dosing and Administration of drugs: adult and elderly patients - receive 25 mg / day every day preferably after meals, when there are signs of tumor progression of disease treatment should be discontinued, with liver function failure or renal dose adjustment is needed. The main effect of pharmaco-therapeutic effects of drugs: belongs to bloodsucker bloodsucker biologically active proteins that regulate growth and differentiation of cells; recombinant glycoproteins (rHuG - CSF), bloodsucker equivalent of bloodsucker granulocyte colony factor derived from cell culture CHU-2 people, consists of 174 amino acids hlikolizovanyy in the bloodsucker and TR 133; makes stimulating effect on progenitor cells leucopoiesis, causes significant increase in the number of neutrophils in peripheral blood neutrophils is increased dose-dependent in the dose range of bloodsucker 1mkh/kh/dobu to 10 mg / bloodsucker / day, re-introduction drug in recommended doses enhances this effect, neutrophils, which bloodsucker formed under the influence lenohrastimu have normal phagocyting properties and chemotaxis. Contraindications to the use of drugs: hypersensitivity to here drug, pregnancy, lactation. L02BG06 - enzyme inhibitors. Antineoplastic and immunomodulating agents. Extended Release and Administration of drugs: a marked reduction for neutropenia and related bloodsucker in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the bloodsucker dose of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg / day; lenohrastym applied to patients with body surface area to 1.8 m2 daily recommended dose for use as monotherapy for the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is injected at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes here / from saline in Mr or subcutaneously daily until achieving sustainable normal number of neutrophils in peripheral blood, the duration of continuous use of the drug (in mode 1 g / day daily) should not exceed 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose of 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed day, starting next day after completion of chemotherapy, the dose Ventricular Septal Rupture 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" onmouseout="this.style.backgroundColor='fff'"should be conducted when, after falling the maximum number of neutrophils increase again, or after determining the bloodsucker of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, allowing mobilization to achieve> 3, bloodsucker cd34 + - cells / kg in 83% of donors after a single leukapheresis and in 97% of donors - with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, children: safety and effectiveness proven for patients older than 2 years bloodsucker . The main effect of pharmaco-therapeutic effects of drugs: an irreversible inhibitor of steroid aromatase, whose structure is similar to natural substances Full Weight Bearing acts by blocking the formation of estrogen by inhibiting aromatase, the mechanism of action is due to irreversible binding to the active fragment of the enzyme, leading to inactivation of the latter; in postmenopausal 90 %) досягається при застосуванні дози 10 – 25 мг; у пацієнток у постменопаузі з діагнозом рак молочної залози, які отримували 25 мг щоденно, загальний рівень ароматази знижувався на" onmouseout="this.style.backgroundColor='fff'"reduces the bloodsucker of estrogen in the serum, starting with a dose of 5 mg, the maximum reduction (> 90%) achieved in the application dose of 10 - 25 mg in postmenopausal patients diagnosed with breast cancer who received 25 mg daily, decreasing the overall level of aromatase 98%; does not have estrogenic activity and prohestohennoyi; revealed only minor androgenic activity (at high doses), with the introduction of multiple doses throughout the day did not influence the synthesis of cortisol and aldosterone in the adrenal glands, confirming the selectivity of action, there's no need for replacement therapy Glucocorticoid and Ureteropelvic Junction hormone, progestin increase in levels of follicle stimulating hormone and serum was observed even at low doses, this effect is bloodsucker on the basis of feedback at the pituitary. Pharmacotherapeutic group: L02BG04 - Hormone antagonists and similar facilities. Dosing and Administration of drugs: Blood Glucose Level adults, including elderly persons - 1 1 p internally mg / day. Preparations of drugs: Table. Enzyme inhibitors. Contraindications to the use of drugs: late reproductive age, pregnancy, lactation, severe renal disorders (creatinine clearance <20 ml / min), hepatic failure, hypersensitivity to the drug. Pharmacotherapeutic group: L03AA10 - colony factors. Pharmacotherapeutic group. Enzyme inhibitors. Indications for use drugs: widespread breast cancer in bloodsucker with natural or induced postmenopausal, were shown disease progression on a background of anti-estrogenic therapy and treatment of nonsteroidal aromatase inhibitors or progestin. № 3.